DARVIAS® (SP-02)
Peripheral T-Cell Lymphoma (PTCL)
LaunchedLaunched in Japan; Phase 2 completed/ongoing or NDA in progress in South Korea, Taiwan, Hong Kong, South America, China, US, EU
Key Facts
Indication
Peripheral T-Cell Lymphoma (PTCL)
Phase
Launched
Status
Launched in Japan; Phase 2 completed/ongoing or NDA in progress in South Korea, Taiwan, Hong Kong, South America, China, US, EU
Company
About Solasia Pharma K.K.
Japanese oncology-focused biopharma company developing and commercializing cancer therapeutics and supportive care products.
View full company profileTherapeutic Areas
Other Peripheral T-Cell Lymphoma (PTCL) Drugs
| Drug | Company | Phase |
|---|---|---|
| LIS22 | Xenothera | Phase 1/2 |
| Lacutamab (IPH4102) | Innate Pharma | Phase 2 |